Journals / Sakarya Tıp Dergisi / 2021 / Cilt: 11 - Sayı: 1

Endocan As A Potential Marker of Early Endothelial Dysfunction In Polycystic Ovary Syndrome (PCOS)

Polikistik Over Sendromunda (PKOS) Erken Endotel Disfonksiyonunun Potansiyel Belirleyicisi Olarak Endocan

Pages
155–161
Publication Date
2021-03-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This may be a sign of early endothelial dysfunction in PCOS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Polycystic ovary syndrome (PCOS) is a common endocrinological disease in women of reproductive age and has a wide range of metabolic effects.
📊
Key Findings & Data:Chronic low-grade inflammation and endothelial dysfunction plays a key role in the pathogenesis of PCOS and they are associated with an increased risk of cardiovascular disease.
💡
Conclusion & Impact:This may be a sign of early endothelial dysfunction in PCOS.
🔬Design:Modeling & Simulation
📍Scope:2003 Verileri
⚙️Variables:endocan · endotel disfonksiyonu · polikistik over sendromu

Abstract

Objective: Polycystic ovary syndrome (PCOS) is a common endocrinological disease in women of reproductive age and has a wide range of metabolic effects. Chronic low-grade inflammation and endothelial dysfunction plays a key role in the pathogenesis of PCOS and they are associated with an increased risk of cardiovascular disease. Endocan, is an inflammatory marker showing endothelial dysfunction. The aim of our study, to compare serum endocan levels in PCOS and healthy control groups and to determine the relationship between some cardiovascular risk factors and serum endocan levels. Materials and Methods: This case-control study included 52 PCOS patients and 59 age-matched healthy controls. Patients were diagnosed as PCOS based on 2003 Rotterdam criteria. Demographic data, history of menstrual irregularity and infertility, polycystic ovary appearance in ultrasonography and hirsutism status were recorded. Endocan levels of PCOS patients and controls were compared. Data analysis was performed by using SPSS-22 for Windows (Statistical Package for Social Science, SPSS Inc. Chicago IL, USA®Z). Results: The median (IQR) value of serum endocan level was 420.7 ng/L (355.2-570.3) in the PCOS group and 320.0 ng/L (219.9-455.9) in the control group (p=0,003). While there was no significant correlation between serum endocan and some cardiovascular risk factors such as waist circumference, hip circumference, BMI, LDL, triglyceride, systolic and diastolic arterial tension but a positive correlation was found between homeostatic model assessment insulin resistance (HOMA-IR) (r= 0.276, p= 0,003). Conclusion: Serum endocan levels are higher in PCOS patients, in line with the literature. Endocan level shows a significant correlation with insulin resistance, one of the metabolic parameters. This may be a sign of early endothelial dysfunction in PCOS.

Özet

Amaç: Polikistik over sendromu (PKOS), üreme çağındaki kadınlarda sık görülen endokrinolojik hastalıktır. PKOS'ta izlenen kronik düşük dereceli inflamasyon ve endotel disfonksiyon artmış kardiyovasküler hastalık riski ile ilişkilidir. Endocan, endotel disfonksiyonunu gösteren inflamatuar bir belirteçtir. Çalışmamızda PKOS ve sağlıklı kontrol grubunu serum endocan düzeyleri açısından karşılaştırmayı ve kardiyovasküler risk faktörleri ile serum endocan düzeyleri arasındaki ilişkiyi belirlemeyi amaçladık. Gereç ve Yöntemler: Bu vaka-kontrol çalışmasında, 52 PKOS hastası ve yaş eşleştirilmiş sağlıklı 59 bireyden oluşan kontrol grubu yer almaktadır. Hastalara, 2003 Rotterdam kriterlerine göre PCOS tanısı kondu. Demografik veriler, menstruel düzensizlikler, infertilite öyküsü, ultrasonografide polikistik over görünümü ve hirsutizm varlığı kaydedildi. PCOS hastaları ve kontrol grubunun serum Endocan düzeyleri karşılaştırıldı. Veri analizi Windows için SPSS-22 (Statistical Package for Social Science, SPSS Inc. Chicago IL, USA®Z) kullanılarak yapıldı. Bulgular: Serum endocan düzeyi ortanca (IQR) değeri PKOS grubunda 420,7 ng / L (355,2-570,3), kontrol grubunda ise 320,0 ng / L (219,9-455,9) idi (p = 0,003). Serum endocan ile bel çevresi, kalça çevresi, BMI, LDL, trigliserit, sistolik ve diyastolik arteriyel basınç gibi bazı kardiyovasküler risk faktörleri arasında anlamlı bir ilişki bulunmazken, insülin direnci (HOMA-IR) ile arasında pozitif korelasyon saptandı (r = 0.276, p = 0,003). Sonuç: Çalışmamızda, serum endocan düzeyleri literatürle uyumlu olarak PKOS hastalarında daha yüksek saptanmıştır. Endocan düzeyi, metabolik parametrelerden biri olan insülin direnci ile anlamlı bir korelasyon göstermektedir. Bu bulgular, PKOS' ta erken endotel disfonksiyonunun bir işareti olarak yorumlanabilir.

🔖

Cite This Article

APAYDIN, M., DEMİRCİ, T., ÇAKAL, E. (2021). Endocan As A Potential Marker of Early Endothelial Dysfunction In Polycystic Ovary Syndrome (PCOS). Sakarya Tıp Dergisi, Cilt: 11 - Sayı: 1, 155–161. https://ajindex.com/articles/261182

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Delibas IB, Yapca OE, Laloglu E. Does endocan level increase in women with polycystic ovary syndrome? A case - control study. Ginekol Pol 2018; 89 (9):500-505
  2. Bicer M, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 2017; 42 (2):145-153
  3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89 (6):2745-2749
  4. Carmina E, Lobo RA. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome? J Womens Health (Larchmt) 2018; 27 (11):1385-1388
  5. Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. New England Journal of Medicine 2016; 374 (25):2430-2440
  6. Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, et al. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology 2014; 30 (11):781-784
  7. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152 (5):749-756
  8. De Freitas Caires N, Legendre B, Parmentier E, Scherpereel A, Tsicopoulos A, Mathieu D, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 2013; 78-79:45-51
  9. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction 2006; 21 (6):1426-1431
  10. Samy N, Hashim M, Sayed M, Said M. Clinical significance of inflammatory markers in polycystic ovary syndrome: Their relationship to insulin resistance and Body Mass Index. Disease Markers 2009; 26:163-170
  11. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86 (10):4666-4673
  12. Kao YH, Chiu WC, Hsu MI, Chen YJ. Endothelial progenitor cel